Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 12, 2017

Visterra begins Phase IIa trial of VIS410 to treat hospitalised patients with influenza A

US-based clinical-stage biopharmaceutical company Visterra has commenced its Phase IIa clinical trial of VIS410 to treat hospitalised patients with influenza A.

US-based clinical-stage biopharmaceutical company Visterra has commenced its Phase IIa clinical trial of VIS410 to treat hospitalised patients with influenza A.

VIS410 is a monoclonal antibody that targets all strains of influenza A and is indicated to treat hospitalised patients with influenza A.

It targets a specific epitope, generally referred to as a Hierotope, on hemagglutinin, which is a surface protein of influenza viruses used for binding and entry into cells.

VIS410 inhibits fusion of the influenza virus with host cell membranes by binding to hemagglutinin and resulting in the end of the viral replication cycle.

"VIS410 is a monoclonal antibody that targets all strains of influenza A and is indicated to treat hospitalised patients with influenza A."

Funded by the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority (BARDA), the Phase IIa clinical trial is being conducted on a global basis that will examine about 150 ambulatory patients diagnosed with influenza A.

Influenza is an infectious disease that triggers both benign and malignant symptoms such as rapidly progressive pneumonia, respiratory failure and, in some cases, death.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The severity of this disease is mostly observed in high-risk groups, including infants, pregnant women, the elderly, patients with underlying medical conditions, and patients with disease or treatment-related immunosuppression.

The patients enrolled in the trial will be divided into one of the three arms of the study and administered with dosages of 2,000mg and 4,000mg of VIS410 or placebo.

The study is primarily focused on establishing the safety and tolerability of VIS410, and its secondary endpoints are to determine clinical symptoms of influenza, virology and pharmacokinetics of VIS410.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU